The small RNA SraG participates in PNPase homeostasis

FANETTE FONTAINE,¹ ELISE GASIOROWSKI,¹ CELINE GRACIA,¹ MATHIEU BALLOUCHE,¹ JOEL CAILLET,¹ ANTONIN MARCHAIS,^{2,3} and ELIANE HAJNSDORF¹

¹CNRS UMR8261 (previously FRE3630) associated with University Paris Diderot, Sorbonne Paris Cité, Institut de Biologie Physico-Chimique, 75005 Paris, France

²Institut de Génétique et Microbiologie, CNRS/UMR 8621, Université Paris Sud, 91405 Orsay, France

ABSTRACT

The *rpsO-pnp* operon encodes ribosomal protein S15 and polynucleotide phosphorylase, a major 3′–5′ exoribonuclease involved in mRNA decay in *Escherichia coli*. The gene for the SraG small RNA is located between the coding regions of the *rpsO* and *pnp* genes, and it is transcribed in the opposite direction relative to the two genes. No function has been assigned to SraG. Multiple levels of post-transcriptional regulation have been demonstrated for the *rpsO-pnp* operon. Here we show that SraG is a new factor affecting *pnp* expression. SraG overexpression results in a reduction of *pnp* expression and a destabilization of *pnp* mRNA; in contrast, inhibition of SraG transcription results in a higher level of the *pnp* transcript. Furthermore, *in vitro* experiments indicate that SraG inhibits translation initiation of *pnp*. Together, these observations demonstrate that SraG participates in the post-transcriptional control of *pnp* by a direct antisense interaction between SraG and PNPase RNAs. Our data reveal a new level of regulation in the expression of this major exoribonuclease.

Keywords: antisense RNA; PNPase; post-transcriptional regulation; SraG

INTRODUCTION

Polynucleotide phosphorylase (PNPase) is a 3′–5′ exoribonuclease that is conserved from bacteria to plants and metazoans (Zuo and Deutscher 2001). PNPase plays many roles in RNA metabolism. Together with RNase II, it is responsible for eliminating the small nonfunctional RNA fragments generated by endonucleases (Andrade et al. 2009). In addition, it is required in many RNA processing reactions to generate mature transcripts and in mRNA surveillance mechanisms to eliminate aberrant transcripts (Braun et al. 1996; Reuven et al. 1997). PNPase is a phosphorylase that uses a phosphate residue to attack the single-stranded 3′-end of RNAs and to liberate a nucleoside-diphosphate. Alone it is capable of degrading secondary structures of moderate stability that are resistant to RNase II. PNPase exists as a homotrimeric complex, and it is part of the degradosome in *Escherichia coli* (Carpousis et al. 1994). Its association with the RhlB helicase, another component of the degradosome, allows PNPase to disrupt very stable secondary structures that cannot be degraded by the free enzyme in *E. coli* (Régnier and Hajnsdorf 2009). PNPase degrades certain small RNAs (sRNA) (Andrade and Arraiano 2008; Andrade et al. 2012), but it can also interact with sRNAs in a nondestructive mode to-

gether with Hfq in *E. coli* or in complex with Rsr protein in *Deinococcus radiodurans*, where Y RNA act as adaptors between the two proteins (Chen et al. 2013; Bandyra et al. 2016).

PNPase also has a template-independent 3′-oligonucleotide polymerase activity *in vitro* (Grunberg-Manago et al. 1955). PNPase activity is dependent on the metabolic state of the cell since it is inhibited by magnesium-chelated citrate and ATP, while it is activated by c-di-GMP (Del Favero et al. 2008; Nurmohamed et al. 2011; Tuckerman et al. 2011).

PNPase is not necessary for growth at optimal temperatures, but it is essential for growth of *E. coli*, *Bacillus subtilis*, and *Yersinia enterocolitica* at low temperatures (Luttinger et al. 1996; Goverde et al. 1998; Zangrossi et al. 2000). PNPase is a cold-shock protein (CSP) that is required for selective degradation of CSP mRNAs, allowing the transition from the acclimatization phase to cell growth resumption after cold shock (Yamanaka and Inouye 2001). PNPase-deficient cells are less viable than wild-type to H₂O₂-mediated killing (Wu et al. 2009). It can also be noted that PNPase is necessary for bacterial virulence in some well-known pathogens, including the *Salmonellae* and the *Yersiniae* (Clements et al. 2002; Rosenzweig et al. 2007; Numata et al. 2014). In

³Present address: Department of Biology, Swiss Federal Institute of Technology Zurich (ETH-Z), CH-8092 Zurich, Switzerland

Corresponding author: eliane.hajnsdorf@ibpc.fr

Article published online ahead of print. Article and publication date are at <http://www.rnajournal.org/cgi/doi/10.1261/rna.055236.115>.

© 2016 Fontaine et al. This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see <http://rnajournal.cshlp.org/site/misc/terms.xhtml>). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

addition, it has been proposed that the pool of nucleoside diphosphates generated by PNPase-mediated degradation of RNA plays an important role in the appearance of spontaneous mutations in *E. coli* (Becket et al. 2012).

The *pnp* gene is part of the *rpsO-pnp* operon (Fig. 1A). Transcription from a promoter (P1), upstream of *rpsO*, encoding S15, generates two transcripts: a monocistronic *rpsO* transcript, which terminates at a Rho-independent terminator (T1) between the two open reading frames (ORFs), and a polycistronic *rpsO-pnp* transcript, which terminates at T2 downstream from the *pnp* gene (Fig. 1A). In addition, a monocistronic *pnp* mRNA is initiated at a promoter (P2) located downstream from the *rpsO* terminator (Fig. 1A). The *rpsO-pnp* intergenic region is crucial for the expression and stability of the *rpsO* and *pnp* transcripts.

The general model for mRNA degradation in *E. coli* postulates that transcripts are irreversibly inactivated by an endonucleolytic cleavage near their 5'-end, predominantly by RNase E, followed by a wave of further endonucleolytic cuts and 3'-5' exonucleolytic degradation of the generated mRNA fragments (Carpousis et al. 2009). However, the degradation of the *rpsO* and *pnp* transcripts does not fit to this model. RNase E initiates the decay of the *rpsO* transcript by cleaving near its 3' extremity, upstream of the transcription terminator (T1) (Fig. 1C [1]). It also cleaves the polycistronic *rpsO-pnp* transcript at the T1 site and downstream from the *rpsO* terminator hairpin, generating an upstream *rpsO* transcript identical to the one derived from the monocistronic transcript (Fig. 1C [2]; Régnier and Hajnsdorf 1991). Degradation of *pnp* mRNA is initiated by RNase III, which very efficiently cleaves both the *pnp* monocistronic transcript and the dicistronic *rpsO-pnp* mRNA within a long stem-loop included in the *pnp* mRNA leader that is downstream from the T1 terminator (Fig. 1C [1,2]). These cleavages trigger the PNPase-mediated degradation of the processed 5'-end of the *pnp* mRNA and the rapid attack by RNase E at the beginning of the *pnp* coding sequence, which leads to the irrevers-

FIGURE 1. Two forms of SraG RNA. (A) Genomic context of *sraG*. The gene encoding SraG (shaded in gray) is located between the coding regions of the *rpsO* and *pnp* genes (encoding ribosomal protein S15 and PNPase, respectively). The *sraG* and *pnp* genes are expressed divergently but the 5'-ends of these transcripts overlap. Promoters P1, P2, and P, as well as terminators T1, T2, and T for *rpsO*, *pnp*, and *sraG*, respectively, are indicated. Note that T1 and T are the same bidirectional terminator. (B) Two forms of SraG. Wild-type N3433 and bacteria lacking SraG (mutation in the -10 sequence of SraG promoter [*P_{SraGmut}*] identified in this study) were harvested in exponential and stationary phase and RNA extracted and separated on an acrylamide gel. Northern blots were probed to detect SraG RNA using an antisense RNA probe equivalent to positions 43–179 of the full size SraG identified here and to 5S RNA. Size of the SraG transcripts was estimated by comparison with radiolabeled markers. (C) Schematic representation of the processing of the *rpsO* and *pnp* primary transcripts. The monocistronic *rpsO*, *pnp* (1), and *sraG* (3) transcripts and the dicistronic *rpsO-pnp* mRNA (2) are shown with the black circle indicating their 5'-triphosphate extremities corresponding to P1 (*rpsO* promoter), P2 (*pnp* promoter), and P (*sraG* promoter). Processing sites by RNase E (RE) and RNase III (RIII) on the primary transcripts are indicated by gray and black scissors, respectively. Data on SraG are from experiments shown in Supplemental Figure S5A–C. Potential hairpins within the transcripts are shown: T1 and T2 are the *rpsO* and *pnp* terminators, and R is the stem-loop in the 5'-region of *pnp* subject to RNase III cleavage. (D) SraG primary transcript is 216 nt long. The sequence corresponds to the (+) strand (as shown in A) from the beginning of the *pnp* ORF to the *rpsO* termination codon. The sequence highlighted in gray corresponds to the SraG primary transcript identified by cRT-PCR. A total of 76 RT-PCR *sraG* clones were sequenced. Vertical arrows denote extremities located by cRT-PCR. Arrows in boxes 1 and 2 correspond to the positions of 5'-ends and in boxes 3 and 4 to 3'-extremities. In most cases, numerous clones were detected at each single position. The transcription initiation site (underlined T in box 1) was only detected in samples after polyphosphatase treatment (see Supplemental Fig. S2). Both the previously annotated 5'-extremity and the newly described +1 transcription start site are shown in bold and underlined. The -10 and the -35 sequences are underlined. The 3'-extremity of the terminator, which is the major 3'-extremity, is shown in bold and underlined, but a few clones harbor 3'-ends downstream, indicating that some read-through occurs. The 190-nt long RNA should correspond to a population of RNA molecules, with different 5'- and 3'-extremities. While a fraction of these RNA fragments, which starts at *P_{SraG}* or very close (panel D, box 1), have their 3'-ends in box 3 (176- to 185-nt long fragments), the rest of the shorter SraG transcripts could correspond to a 5'-end in box 2 (panel D) and a stop at the terminator (174- to 189-nt long fragments) (panel D, box 4). These RNA fragments of ~190 nt are hereafter collectively designated as SraGp. Boxes TTG and TAA in gray indicate the *pnp* START codon and *rpsO* STOP codon located on the (–) strand, respectively. The *pnp* transcription initiation site and the *pnp* ribosome-binding site (RBS) located on the (–) strand are also indicated in gray.

ible inactivation of the *pnp* message and a decreased synthesis of polynucleotide phosphorylase (Fig. 1C; Portier et al. 1987; Hajnsdorf et al. 1994a; Jarrige et al. 2001; Carzaniga et al.

2009). Translation of *pnp* is also tightly regulated. In the absence of RNase III cleavage, PNPase controls its own expression at the translational level, and this repression does not require the catalytic activity of the enzyme (Carzaniga et al. 2015). This RNase III-independent negative control may result from a competition between PNPase and S1 for *pnp* mRNA binding (Carzaniga et al. 2015). Higher expression of PNPase after a cold shock results from both a slight transcriptional induction from the P2 promoter and the stabilization of the *pnp* transcript (Zangrossi et al. 2000). The destabilizing effect of PNPase on its own mRNA is also less efficient at low temperatures, leading to a decrease in repression and an increase in the expression level (Beran and Simons 2001; Mathy et al. 2001). In addition, CsrA binds two sites in the *pnp* 5'UTR, after its processing by RNase III and PNPase, where one CsrA site overlaps the *pnp* Shine-Dalgarno sequence (SD) such that CsrA binding inhibits *pnp* translation (Park et al. 2015).

Although an antisense RNA (asRNA) has been described, called SraG, which is encoded between *rpsO* and *pnp* genes and convergently transcribed toward *rpsO*, no evidence of an effect on *rpsO* or *pnp* regulation by this noncoding RNA was reported (Fig. 1A; Argaman et al. 2001). Most of the sRNAs discovered in bacteria modulate gene expression at the post-transcriptional level by base pairing to mRNAs. This class of sRNAs includes asRNA transcribed from the complementary DNA strand of their targets and sRNAs transcribed at loci distant from their targets. These latter sRNAs usually require the Hfq protein to interact with their targets (Vogel and Luisi 2011). In an *hfq* null mutant, the *pnp* mRNA level was not affected, suggesting that control by a *trans*-acting Hfq-dependent small RNA is unlikely (Le Derout et al. 2010). However, the SraG transcript, which originates within the upstream untranslated sequence of *pnp*, could act as an asRNA controlling expression of either or both *rpsO* and *pnp* because it is complementary with the intergenic RNA sequences, which control the expression of S15 and PNPase (Fig. 1A).

Many of the first *cis*-acting asRNAs identified were regulators of plasmid copy number and replication (Brantl 2007). Some of the best known examples of antisense RNA regulation in *E. coli* come from the type I toxin-antitoxin (TA) systems, where the antitoxin is an asRNA and the toxin promotes cell killing, cell stasis or long-term cell persistence (Gerdes et al. 2005; Gerdes and Wagner 2007). In each of these cases, the asRNA affects the translation of its target (Wagner et al. 1992; Kawano et al. 2007). In other cases, the primary role of asRNAs is to either positively or negatively alter the RNA stability. For example, overexpression of the GadY sRNA results in the processing of the *gadXW* mRNA, giving rise to separate *gadX* and *gadW* transcripts that are more stable and that accumulate to higher levels than the full-length mRNA (Opdyke et al. 2004). The RyeA/SdsR sRNA pair is cleaved by RNase III and then degraded, with the result that SdsR expression is inversely correlated

with RyeA expression (Vogel et al. 2003). Another possible mechanism of gene expression inhibition by asRNAs involves transcriptional inhibition of the genes encoded on the opposite strand by converging transcriptional interference (Thomason and Storz 2010).

To investigate a possible role of SraG on the expression and/or stability of *rpsO* and *pnp*, we analyzed the expression and function of SraG. We found that SraG RNA is transcribed from a different promoter than that previously described, producing a 216-nucleotide (nt) transcript and an ~190-nt transcript. SraG RNA overproduction affected both the stability and the translation of *pnp*. In vitro experiments showed that interaction of SraG with *pnp* mRNA modifies RNase III cleavage of both SraG and *pnp*, and it does not allow the 30S ribosome to interact physically with the Shine-Dalgarno sequence. In addition, we looked for other possible targets of SraG, but we were unable to find other genes potentially regulated by SraG. Altogether, we show that SraG acts as an asRNA to *pnp* mRNA to modulate its expression.

RESULTS

Characterization of the SraG sRNA

SraG has been described as a 174-nt transcript that is cleaved to produce a 147-nt processed RNA that is potentially polyadenylated at its 3' extremity (Argaman et al. 2001). We first examined the abundance of both transcripts by Northern blots and unexpectedly detected bands of ~215 and ~190 nt, i.e., distinctly longer than the previously described transcripts (Fig. 1B). Transcripts of the same size were reproducibly found in exponential and stationary phase and in N3433 and MG1655 strains (Fig. 1B; Supplemental Fig. S1). We performed circular RT-PCR (cRT-PCR) and found no clones starting at the previously annotated transcription initiation site (Fig. 1D). Comparisons of RNA treated or not by polyposphatase allowed us to identify the SraG transcription initiation site at 42 nt upstream of the previously annotated 5'-extremity of SraG (Fig. 1D, box 1 marked with asterisk; Supplemental Fig. S2). Interestingly, this transcription-initiation start (P_{SraG} , P in Fig. 1A) was originally predicted by bioinformatic analysis (Argaman et al. 2001). Most transcripts were found to harbor 3'-extremities at the previously described terminators (box 4, Fig. 1D). Altogether, this indicated that the longest transcript detected on Northern blots was a primary transcript of 216 nt starting at P_{SraG} and ending at the terminator. The 190-nt long RNA corresponded to a population of RNA molecules with different 5' and 3' extremities. These RNA fragments of ~190 nt are hereafter collectively designated as SraGp. They might result from maturation events at either the 5'- or 3'-end of the 216-nt primary transcript.

Mutation of the -10 box of P_{SraG} (giving P_{SraGmut}) eliminated the 216-nt long SraG and decreased by ninefold the level of SraGp (Fig. 1B), confirming that P_{SraG} promoted

transcription of SraG and that the 190-long SraGp RNA was produced by processing of this primary transcript. The residual SraG signal detected when P_{SraG} was inactivated could correspond to the maturation of a longer transcript predicted to initiate 339 nucleotides upstream of P_{SraG} .

RNase III, RNase E, and PNPase are involved in maturation and degradation of SraG

We investigated whether the endoribonucleases involved in maturation and degradation of *E. coli* mRNAs and sRNAs, namely RNase III (*rnc*), RNase E (*rne*), and RNase G (*rng*), were involved in SraG sRNA processing to generate the SraGp forms (Fig. 1B). Isogenic strains deficient for each of these RNases were used as well as strains with combinations of double and triple mutations. The effect of RNase E inactivation was examined by using the *rne3071^{ts}* allele. For comparison, RNAs from all strains were prepared from bacteria grown at 30°C and shifted to 42°C to inactivate the thermo-sensitive RNase E. SraG and SraGp both accumulated in *rne* and *rnc* mutants, suggesting that both RNase III and RNase E played a role in SraG degradation (Fig. 2A). However, the relative intensity of the two bands did not change, which therefore excluded the direct involvement of RNase III or RNase E in the cleavage of the primary transcript to generate SraGp.

FIGURE 2. RNase III, RNase E, and PNPase are involved in SraG degradation. Northern blot analysis of SraG sRNA. N3433 strains carrying mutations in the genes indicated at the top of the autoradiograph were grown at 30°C in LB medium and shifted to 42°C for 15 min (A) or grown at 37°C (B). Total RNA (10 µg) was separated on acrylamide gels and analyzed by Northern blotting. Blots were probed for SraG and 5S rRNA.

Similarly, none of the exoribonucleases RNase II, PNPase, or RNase R individually modified the ratio between SraG and SraGp (Fig. 2B, data not shown). We observed in the *rnc* and *rne* mutants additional shorter bands of ~160, 147, and 120 nt (Fig. 2A,B). While in the *pnp* mutant a significant accumulation of fragments of ~147, 120, and 110 nt were observed, and their level was even higher in the double *rnc-pnp* mutant, suggesting that RNase III was not responsible for their generation and that the *rnc* effect was superimposed on the *pnp* effect (Fig. 2B). Only the 160-nt fragment was absent in the double *rnc-pnp* mutant, suggesting a processing by PNPase of SraG in the *rnc* mutant.

We also tested the role of other RNases such as RNase BN (*elaC* or *rbn*), RNase P (*rnpA*), and YbeY (*ybeY*), which is a metal-dependent single-strand-specific endoribonuclease (Davies et al. 2010; Pandey et al. 2011). Their inactivation had no effect on the level or the balance between SraG and SraGp (Supplemental Fig. S3), indicating that none of these RNases were involved in SraG maturation and degradation.

Finally, we investigated whether other factors, such as Hfq (*hfq*), poly(A) polymerase (PAP I) (*pcnB*), and YhbJ (*rapZ*), which is involved in the regulation of GlmS (Gopel et al. 2013), affected the level of SraG and/or SraGp production (Massé et al. 2003; Reichenbach et al. 2008). YhbJ inactivation had no effect. Hfq and PAP I inactivation had only a small effect on the level of SraG and on its processing (0.94- and 1.27-fold compared to wt, respectively) (Fig. 2B; Supplemental Fig. S3A). The cRT-PCR experiments showed that 24 of the 76 clones with 3'-extremities close to the terminator (Fig. 1D, box 4) contained one to four noncoded adenosine residues, which were presumably added by PAP I. We concluded that polyadenylation of SraG did not facilitate the exoribonucleolytic degradation of the sRNA.

In conclusion, none of the mutations tested affected the relative abundance of the long and processed SraGp forms, implying that none of the tested RNases was responsible for the maturation events producing the 190-nt transcripts. The only conditions where the ratio between SraG and SraGp (usually 50% of each) was modified were the replacement of the TTG *pnp* start codon for a TGA stop codon or when the stringent response was provoked. This suggested that *pnp* translation could modify SraG maturation. This point will be discussed later.

Regulation of *sraG* expression

To attempt to characterize the biological role of SraG, we first investigated the regulation of its transcription. Both SraG forms are poorly expressed compared to *rpsO* and *pnp* mRNAs in LB medium in both exponential and stationary phases and in minimal media (data not shown). It has been reported that the levels of both 174- and 146-nt SraG were higher at 42°C and 15°C (Argaman et al. 2001). We have confirmed this observation for the 216-nt and 190-nt long SraGs detected in our experiments (data not shown). It has also

been reported that SraG is up-regulated at the exterior of a biofilm when compared to the interior, suggesting that SraG expression may be regulated by differential stress conditions like nutrient availability (Ito et al. 2009). In order to investigate a possible role of nutrient starvation, we induced the stringent response by adding serine hydroxamate (SHX). SHX acts as a competitive inhibitor of serine aminoacyl-tRNA synthetase, and thereby it induces the stringent response by starving ribosomes for tRNA^{Ser}. We found that addition of SHX in the exponential phase for 30 min increased the relative level of the long SraG by about twofold. This suggested that SraG transcription and/or stability, as well as SraGp production/stability, may be modulated as a consequence of the induction of the stringent response (Supplemental Fig. S1).

To examine the potential role of SraG as an asRNA affecting *rpsO* and/or *pnp* expression, the SraG sRNA was ectopically expressed from the inducible P_{LacO-1} modified promoter (Guillier and Gottesman 2006). SraG DNA, starting at the transcription start site and ending at the transcription terminator identified by cRT-PCR, was cloned into the pBRplac plasmid (to give pBRSraG). As a control, we cloned the SraG short form that had 42 nt deleted from the 5'-end (pBRSraG-S); this corresponded to the previously annotated 5'-extremity described by Argaman et al. (2001). Overexpression of SraG or SraG-S had no effect on growth in rich medium in either liquid culture or on plates incubated at 37°C or 18°C, nor in response to heat shock or cold shock, nor on motility or biofilm formation (data not shown). Overexpression for 20 min resulted in about a 30-fold and 40-fold enhancement of SraG and SraG-S, respectively (Supplemental Fig. S4). Surprisingly, very low levels of SraGp relative to SraG (respectively indicated by [**] and [*] in Supplemental Fig. S4) were detected when the sRNA was ectopically transcribed from a foreign promoter. Also, the levels of plasmid-expressed SraG and SraG-S were five and three times more abundant, respectively, in the *rnc* mutant (Supplemental Fig. S4). In the case of full-size SraG, but not for SraG-S, this increase in the level of RNA was associated with a longer half-life in the *rnc* mutant (Table 1).

SraG overexpression affects maturation of the *rpsO*-*pnp* mRNA and the levels of *pnp* mRNA

The levels of *rpsO* and *pnp* mRNAs were determined 7 min after addition of IPTG to cells containing the empty plasmid or the SraG-expressing constructs to limit the level of SraG overexpression (Fig. 3A). SraG had no significant effect on the abundance of the *rpsO* transcripts (404 nt and 500 nt) (Fig. 3A, fragments 0 and 1; Table 1). The levels of the *rpsO* transcript were lower in the *rnc* mutant. This is presumably because the level of PNPase was higher in the *rnc* strain and because PNPase was responsible for the poly(A)-dependent degradation of the *rpsO* transcript (Hajnsdorf et al. 1994b; Robert-Le Meur and Portier 1994). This decrease was partly rescued by overproduction of either SraG or SraG-S, suggesting that they could negatively control the level of PNPase. However, there was no significant modification of *rpsO* stability upon SraG overproduction in the wt or in the *rnc* mutant (Table 1). This indicated that the possible pairing of SraG-S or SraG to *rpsO* and *rpsO*-*pnp* transcripts did not affect the RNase E cleavage of the mRNA upstream of the terminator T1 (Fig. 1C), which is the limiting step in the degradation of the *rpsO* transcript (Régner and Hajnsdorf 1991; Hajnsdorf et al. 1994b). In addition, asRNA overproduction did not significantly affect RNase III cleavage efficiency at the RIII1 site (Figs. 1C, 3A, fragment 1).

In the absence of RNase III, the *rpsO*-*pnp* transcript was cleaved downstream from the hairpin recognized by RNase III (Fig. 3A giving the 560-nt processed fragment 2) (Régner and Grunberg-Manago 1990). Overproduction of either SraG or SraG-S produced cleavages at new positions that generated the 580-nt and 620-nt processed *rpsO*-*pnp* transcripts (Fig. 3A, processed forms 3 and 4).

SraG-S and SraG have opposite effects on the accumulation of *pnp* mRNA. SraG-S overproduction slightly increased the level of *pnp* mRNA in the wt and the *rnc* mutant, presumably as a consequence of an increased stability (Fig. 3B,C; Table 1). On the other hand, SraG overproduction decreased the level of *pnp* and its half-life in the wt (Fig. 3B,C), although in the *rnc* mutant, the decreased level of *pnp* mRNA did not

correlate with the half-life of the *pnp* transcript (Fig. 3B; Table 1). When SraG was overexpressed, RNase III still cleaved *pnp* RNA at the RNase III2 downstream site (Fig. 1C), but new stops of reverse transcriptase were observed, which could correspond to additional cleavages by RNase III or by another RNase (Fig. 3C).

SraG overexpression decreases *pnp* expression

We analyzed the effect of SraG-S and SraG overproduction on *pnp* expression

TABLE 1. Overexpression of the 216-nt SraG transcript (SraG) and SraG-S has opposite effects on the stability of the *pnp* messenger, without impact on *rpsO*

	wt ^a			<i>rnc</i> ^a		
	pBR	pBRSraG-S	pBRSraG	pBR	pBRSraG-S	pBRSraG
<i>pnp</i> ^b	1.19 ± 0.11	2.26 ± 0.10	0.78 ± 0.17	6.95 ± 0.08	7.82 ± 0.08	8.34 ± 0.07
<i>rpsO</i> ^b	1.11 ± 0.14	0.94 ± 0.09	1.05 ± 0.13	1.42 ± 0.08	1.29 ± 0.10	1.96 ± 0.09
SraG ^b		1.31 ± 0.12	1.32 ± 0.14		1.17 ± 0.14	5.46 ± 0.07

^aStrains used are FF4 (wt) and FF19 (*rnc*) carrying pBR, pBRSraG-S, or pBRSraG grown at 37°C. At OD₆₀₀ 0.4, SraG expression was induced by IPTG and rifampicin was added 7 min later (time 0). RNA was extracted at different times.

^bNorthern blots were probed for *pnp*, *rpsO*, SraG, and 5S RNA. Half-lives (min) of *pnp*, *rpsO* (404 nt mRNA), and SraG transcripts were calculated. Values are the mean with standard deviation of three independent experiments.

by adding increasing amounts of IPTG at the beginning of the culture. Expression of *pnp* was determined by using a translational *pnp-lacZ* fusion and by Western blot analysis. Figure 4 shows that under these conditions SraG overexpression decreased slightly the expression of *pnp-lacZ* and PNPase, while SraG-S had no effect on β -galactosidase activity but increased by twofold the level of PNPase. The effect of SraG overproduction on *pnp-lacZ* expression was slightly stronger in the *rnc* mutant (about twofold decrease) when *pnp* mRNA was 10 times more abundant than in the wt, while SraG-S had nearly no effect. We concluded that the 5'-part of the sRNA was essential to modulate PNPase expression and *pnp* mRNA stability. Hfq inactivation had no effect on SraG and SraG-S control of *pnp-lacZ* expression (data not shown).

Binding of SraG to *pnp* induces a new RNase III cleavage of the mRNA in vitro

These results suggested that upon SraG overexpression, new RNase III cleavages might occur when *pnp* is hybridized with SraGs and/or that translation initiation could be modified. To test these hypotheses, we performed in vitro experiments. RNase III cleavage is the crucial first step in the control of PNPase expression. It cleaves the stem loop (R) present in the *pnp* leader sequence at two sites, RIII1 and RIII2, located 39 and 77 nt downstream from the P2 transcription start site (Fig. 1C). These cleavages trigger *pnp* mRNA decay resulting in a decreased synthesis of PNPase. Since SraG was antisense to the 5' region of *pnp* carrying the RNase III processing sites, base pairing of *pnp*

UTR with SraG could interfere with RNase III processing of *pnp*. SraG could also be a substrate of RNase III because endogenous and overexpressed SraG were more abundant in the *rnc* strain and the overexpressed SraG was more stable in *rnc* than in wt strains with half-lives of 5.46 min and 1.32 min, respectively (Table 1; Supplemental Fig. S4).

We examined whether SraG affected the cleavage of *pnp* mRNA by RNase III in vitro and whether SraG was itself a substrate for RNase III. We used a *pnp* RNA fragment (*pnp**, Fig. 5), which starts at the transcription start site P2 and extends into the open reading frame. RNase III was shown to cleave the *pnp* mRNA at two sites, RIII1 and RIII2, both in vivo and in vitro (Fig. 5A,B; Supplemental Fig. S5E; Hajnsdorf et al. 1994a). SraG and SraG-S alone were cleaved by RNase III at sites called RIII1' and RIII2', which are the mirror of sites RIII1 and RIII2 on the *pnp* transcript (Fig. 5B; Supplemental Fig. S5B,C,E). This indicated that SraG formed the same stem-loop structure as *pnp* mRNA, as predicted by several RNA folding programs/algorithms. SraG was also cleaved by RNase III at a site RIII3' in the SraG terminator, which was a sequence outside the duplex with *pnp* mRNA (Figs. 1C, 5B; Supplemental Fig. S5B,C,E). RNase III was also tested on the *pnp* and SraG RNAs together, under conditions where all the molecules were fully engaged in a duplex (Supplemental Fig. S5A). After duplex formation with SraG or SraG-S, RNase III cleaved

FIGURE 3. Overexpression of SraG affects the abundance of *pnp*, but not *rpsO* mRNAs. Northern blot analysis of *rpsO* (A) and *pnp* (B) RNA in FF4 (wt) and FF19 (*rnc*) containing the pBRplac (pBR), pBR-SraG (pSraG), and pBR-SraG short (pSraG-S) plasmids. Expression of SraG was induced by adding IPTG (100 μ M) for 7 min. Radioactivity corresponding to each transcript was quantified and normalized relative to 5S and compared to the strain carrying the empty pBRplac plasmid. The mean value (in arbitrary units) of three independent experiments relative to the corresponding pBR containing cells is indicated below the gel. The Northern blot showing *pnp* detection in the *rnc* mutant was underexposed compared to wt to allow comparison. In A, the arrows indicate the various processed forms containing *rpsO* derived from the dicistronic transcript, which are numbered according to their size and schematically represented on the right side of the Northern blot. Cleavage by RNase III on the left side of the R secondary structure (RIII1 site) generated *rpsO-pnp* processed form 1 is detected in the wt strain. In the *rnc* strain, longer transcripts (2,3,4) are detected corresponding to cleavages within or downstream from the R secondary structure. (C) Total RNA from N3433 (wt), N3433 lacking SraG (mutation in SraG promoter P_{SraGmut}) (left panel), and FF4 transformed with pSraG, pSraG-S, and empty pBRplac vector (same RNA preparations as in A and B) were used as templates for reverse transcription primed with the radiolabeled RNX1 primer. Reverse transcripts corresponding to the RNase III cleavage site (Fig. 1) are indicated, the asterisk (*) and bracket indicate other reverse transcriptase stops. Radioactivity corresponding to RNase III-processed *pnp* transcript was quantified and compared to the wt strain without plasmid or carrying the empty pBRplac plasmid. These values (in arbitrary units) are indicated below the gel.

FIGURE 4. Overexpression of SraG represses *pnp* expression. Isogenic FF4 (wt) and FF19 (*rnc*) strains carrying the *pnp-lacZ* fusion were transformed with the pBRplac (pBR), pBR-SraG (pBRSraG), and pBR-SraG short (pBRSraG-S) plasmids. SraG and SraG-S synthesis were induced by addition of IPTG at the beginning of the cultures. Samples were taken in the middle of the exponential phase to determine β -galactosidase activity and PNPase levels. (A) β -Galactosidase activity is the mean value of three independent cultures with standard deviation. (B) Western blot analysis of PNPase and L20 has been made on FF4 strain (wt). Quantification of PNPase normalized to L20 is indicated below the gel.

the *pnp* RNA at a new site close to its 5'-end (RIIIA) (Fig. 5A, B; Supplemental Fig. S5E). RNase III enzyme can cut both strands of double-stranded substrates (Court et al. 2013); accordingly a cleavage was also detected on SraG and SraG-S (site RIIIA') (Fig. 5B; Supplemental Fig. S5B,D,E). In addition, SraG and SraG-S in the duplex were also cleaved by RNase III at sites near their 5' extremities (sites RIIIB' and C' for SraG and RIIID' for SraG-S), while no corresponding cleavages in the *pnp* RNA were observed (Fig. 5B; Supplemental Fig. S5B,D,E). These results showed that RNase III cleaved in vitro both the SraG-*pnp* and SraG-S-*pnp* duplexes at new positions. Among them, one site was close to the 5'-end of the *pnp* mRNA, in a region predicted to be single stranded in the transcript. We propose that this cleavage by RNase III in the *pnp*-SraG duplex may facilitate further cleavage by another ribonuclease, such as RNase E, as previously shown (Hajnsdorf et al. 1994a). The SraG RIIIB' cleavage site, outside the duplex, was as efficiently cleaved in the absence or presence of *pnp* mRNA (Fig. 5B; Supplemental Fig. S5B,E). However, these results do not explain why SraG, but not SraG-S, induced a decrease in the level of *pnp* mRNA (Fig. 3) and PNPase expression (Fig. 4) in the wt strain.

Binding of SraG to *pnp* mRNA prevents the formation of the translational initiation complex

SraG binding to the *pnp* leader region was close to but did not overlap the Shine-Dalgarno sequence (Fig. 1C,D), so it was

not obvious that SraG binding should affect *pnp* mRNA translation. In order to look for an SraG-dependent inhibition of *pnp* translation, we used a toe-printing assay. In the presence of initiator tRNA^{fMet}, 30S ribosomal subunits blocked reverse transcription of the *pnp* RNA at 15 nt from the *pnp* initiation codon (UUG) (Fig. 6, lanes 11,16). This signal provided a measure for the formation of the initiation complex, since it was dependent on both 30S subunits and initiator tRNA. Performing the toe-print reaction with SraG RNAs in the absence of 30S/tRNA^{fMet} allowed us to detect the 5'-end of SraGs hybridized to the *pnp* RNA (Fig. 6, lanes 2–5, 7–10). The addition of increasing amounts of SraG in the reaction with 30S and tRNA^{fMet} resulted in the disappearance of the *pnp* toe-print. However, the presence of SraG-S did not affect the *pnp* toe-print. This result showed that SraG (but not SraG-S) annealing to the messenger interfered with the formation of the ternary initiation complex by preventing the 30S subunit from loading onto the *pnp* transcript, and thus this impeded *pnp* translational initiation. As a consequence, SraG could specifically affect the level of *pnp* RNA as shown in Figure 3B when SraG was overproduced because untranslated mRNAs are usually subject to degradation.

A possible reciprocal regulation between PNPase and SraG

So far we have shown that SraG modifies (i) *rpsO-pnp* maturation in the absence of RNase III; (ii) the decay-rate of *pnp* mRNA and its cleavage by RNase III; and (iii) the initiation of *pnp* translation in vitro (Figs. 3–5; Table 1) and hence the PNPase level. We next investigated whether *pnp* transcription or translation affected *sraG* expression. To gain insight into a possible reciprocal regulation of SraG by *pnp*, we performed a Northern blot analysis with RNA harvested from a wt strain and strains where the *pnp* P2 promoter was inactivated (P2_{mut}) or the TTG *pnp* start codon was mutated to TGA (TTG_{mut}). We also checked the effect of inhibiting SraG expression (P_{SraGmut} with a mutation in the –10 box of P_{SraG}) on *pnp* expression. None of the substitutions affected the overall secondary structure of SraG and/or the 5'-part of the *pnp* mRNA (mFold predictions) so that *pnp* autoregulation would not be affected. The mutation in P_{SraGmut} was close to, but did not overlap, the *pnp* Shine-Dalgarno (Fig. 1D; Portier and Régnier 1984). Figure 7A shows that initiation of *pnp* transcription at P2 had no impact on the levels of SraG since SraG and SraGp were equally abundant in the wild-type strain and in the P2_{mut}. Both strains exhibited similar levels of *pnp* mRNA since *pnp* was still transcribed from the P1 promoter as a dicistronic *rpsO-pnp* transcript. The P_{SraGmut} mutation eliminated SraG expression and led to a 30% increase in the amount of *pnp* RNA and the level of PNPase. In the absence of *pnp* translation (strain TTG_{mut}), the *pnp* mRNA was degraded. This mutation almost eliminated production of SraGp, but

FIGURE 5. Both SraG and SraG-S promote new RNase III cleavages in *pnp* mRNA in vitro. (A) RNase III hydrolysis of 5'-end-labeled *pnp* mRNA (*pnp*^{*}) free or in the presence of a molar ratio of SraG or SraG-S. Increasing amounts of RNase III (10⁻⁶–5.10⁻³ units) were added to the *pnp*^{*} RNA alone or in complex with SraG or SraG-S. Lanes T1 and NaOH indicate RNase T1 and alkaline ladders, respectively, of *pnp*^{*}. See Supplemental Figure S5 for cleavages on the SraG RNAs. (B) Schematic representation of the RNase III processing sites on *pnp* (light gray), SraG (black), and SraG-S (dark gray), and *pnp*-SraG and *pnp*-SraG-S duplexes. Light gray crosses represent cleavages observed on both the single RNA molecules and when they are in duplex, black crosses indicate cleavages only observed after duplex formation. A dot represents the 5'-triphosphate extremity of the various RNA molecules.

abundant shorter transcripts were generated. Such a difference was not observed with a *pnp* null mutant that was disrupted by a Tn5 transposable element in the coding sequence (Fig. 2B). This indicated that *pnp* translation was correlated with, or was required for, the processing of SraG into SraGp. Another line of evidence supported this observation; addition of SHX, which inhibits translation and induces the stringent response, also reduced processing of SraG (Supplemental Fig. S1). How this control was achieved remains to be determined.

Interestingly, in the SraG promoter mutant (*P*_{SraGmut}), there was a small (1.3-fold) increase in *pnp* mRNA and PNPase levels (Fig. 7), which was probably caused by the absence of the negative regulation by SraG on *pnp* maturation and/or translation. Altogether, these results showed that expression of *pnp* and SraG mutually affected each other with, on the one hand, SraG controlling *pnp* maturation/translation and, on the other hand, *pnp* translation affecting SraG processing to SraGp.

Does SraG have any other roles?

We wanted to determine whether SraG could also control expression of other targets in *E. coli*. One characteristic of sRNAs acting in *trans* in *E. coli* is a requirement for Hfq. Hfq has been shown to stabilize many sRNAs and to facilitate their interaction with their mRNA target (Vogel and Luisi 2011), although in some cases Hfq may be dispensable (Darfeuille et al. 2007). We investigated the ability of SraG and SraG-S to bind purified Hfq. The dissociation constants for Hfq on SraG and SraG-S were 0.49 nM and 1.08 nM, respectively, as assessed by gel retardation assay with purified Hfq (Supplemental Fig. S6; Hajsndorf and Régner 2000). These binding constants are consistent with previous results showing that Hfq immunoprecipitates with SraG sRNA (Zhang et al. 2003). However, as shown above, Hfq deletion had no impact on either the level of SraG or on its processing (Fig. 2B). Moreover, Hfq deletion did not affect the level of *pnp* mRNA (Le Derout et al. 2010) nor SraG-mediated inhibition of *pnp* expression, as assessed by *pnp-lacZ* expression (data not shown).

SraG of *Yersinia pseudotuberculosis* has been shown to regulate the YPK_1206-1205 operon (Lu et al. 2012). We investigated a possible role of SraG on RNA targets transcribed from elsewhere on the *E. coli* chromosome by using various strate-

gies. We first showed that there was no difference in the functional expression of transcripts by looking at the pattern of total protein labeling in bacterial cultures after SraG or SraG-S overexpression for 1–24 min (Supplemental Fig. S7). To look for specific targets, we performed a computational search for potential SraG and SraG-S targets and conducted a microarray analysis of RNAs prepared after overexpression of SraG or SraG-S for 7 min in exponential phase (see Materials and Methods). Under these conditions, the level of *pnp* was reduced after overexpression of SraG but not that of SraG-S, which validated the experimental approach. Ten potential targets, highly ranked by both methods, were further tested; *alx*, *araH*, *dadA*, *dsbC*, *fadH*, *efeO*, *ydiY*, *fhuC*, *deaD*, *dkSA*. However, none of them exhibited a significant variation in levels of mRNA by Northern blot analysis after 7 min of SraG overexpression (data not shown). Taken together, our findings show that SraG function seems to be restricted to controlling *pnp* in *E. coli*, at least under our experimental conditions. However, it was still possible that

FIGURE 6. SraG blocks 30S binding to the *pnp* 5'-leader in vitro. In vitro synthesized *pnp* RNA fragment (positions 1–234 relative to the transcription start) was used in a toe-print assay in the presence and absence of SraG and SraG-S RNAs. *pnp* RNA was incubated with increasing concentrations of SraG or SraG-S (as a control RNA) giving a molar ratio sRNA:*pnp* RNA of 0 (lanes 1, 6, 11, 16), 0.5 (lanes 2, 7, 12, 17), 1 (lanes 3, 8, 13, 18), 2 (lanes 4, 9, 14, 19), and 5 (lanes 5, 10, 15, 20). Addition of tRNA^{Met} and 30S ribosomal subunits is indicated by (+) (lanes 11–20). GATC lanes are sequencing ladders obtained by asymmetric PCR using the same labeled primer. The TGT start codon of *pnp* is shown. The arrow indicates the 30S toe-print on the *pnp* RNA.

low abundance mRNAs and/or genes only expressed under specific (stress) conditions could be targeted.

Finally, we addressed a possible indirect effect of reducing levels of PNPase by SraG overproduction since a previous report showed that loss-of-function mutations in *pnp* resulted in an increased level of tRNA^{Leu} precursors (Maes et al. 2012). Various amounts of IPTG were added at the beginning of cultures of the strain carrying the pBRSraG plasmid to produce a graduated variation in *pnp* expression. Supplemental Figure S8 shows that the steady-state level of tRNA^{Leu} precursor was unaffected in cells expressing SraG-S from the plasmid, while a slight increase was detected in cells expressing SraG. This finding was in agreement with a reduction in PNPase activity resulting from an increased expression of SraG.

DISCUSSION

We demonstrate here that the SraG sRNA, which is transcribed from the antisense strand in the intergenic region between *rpsO* and *pnp*, is longer than was previously annotated at the 5'-end. We have located the promoter driving its expression in vivo and confirmed by mutagenesis that the shorter form of SraG (SraGp) is a processed product of the primary transcript. Processing of the primary *sraG* transcript occurs at both the 5'- and 3'-ends. We show that overexpres-

sion of SraG decreases the level of the *pnp* transcript. Consistently, mutating the P_{SraG} promoter on the chromosome results in an increase in the levels of *pnp* mRNA and in PNPase, and we show that addition of SraG prevents the formation of the *pnp* translation initiation complex in vitro and also induces cleavages at new positions within the *pnp* mRNA in the region base paired with SraG. By systematically comparing the effects of the expression of full-size SraG and the RNA transcribed from the previously annotated 5'-end (42 nt downstream), we show that the 5'-part of the sRNA is essential to modulate PNPase expression and *pnp* mRNA stability. In conclusion, SraG RNA controls PNPase expression by a direct antisense interaction, which affects the processing and the translation of the *pnp* messenger. However, SraG overexpression does not completely shut off *pnp* expression. For example, it is unable to mimic the cold-sensitive phenotype of a *pnp* mutant. But our results demonstrate that SraG is a new player that fine-tunes PNPase regulation.

Antisense regulation of an endoribonuclease (SymE) that forms the toxin component of the SymE/SymR TA type I pair has been characterized (Kawano et al. 2007), but the antisense regulation of the expression of PNPase is, as far as we know, the first example of such a mode of regulation of a major exoribonuclease conserved from bacteria to plants.

Half of the SraG RNA exists in a form lacking ~30 nt from either the 5'- or the 3'-ends. The long and short forms are always observed and in approximately equal molar amounts. The identity of the nuclease(s) responsible for the generation of these truncated forms is still unknown. We tested various ribonucleases (RNase E, RNase III, RNase G, RNase II, PNPase, RNase R, RNase BN, and RNase P), and other factors [poly(A) polymerase, Hfq, YbeY, YhbJ] that are known to modify processing and accumulation of sRNA, and we were unable to define a nucleolytic activity generating SraGp. This recalls the situation for the GadY-dependent processing of *gadX-gadW* where, in addition to RNase III, another unidentified endoribonuclease is involved in generating the monocistronic *gadX* and *gadW* transcripts (Opdyke et al. 2011). However, events occurring in *cis*, such as premature termination of SraG or transcriptional interference between SraG and *pnp*, could be involved in SraGp production since only a low level of SraGp is detected from ectopically overexpressed SraG (Supplemental Fig. S4). Similarly, the level of SraGp is decreased when *pnp* translation initiation

FIGURE 7. Reciprocal regulation of *pnp* and SraG expressions. (A) Northern blot analysis of SraG and *pnp* mRNA and (B) Western blot analysis of PNPase in N3433 wild-type, sraG ($P_{SraGmut}$) and *pnp* mutants ($P2_{mut}$ and TTG_{mut}). Quantifications of *pnp* radioactivity and PNPase levels (arbitrary units) normalized relative to 5S and L20, respectively, are indicated below the gels.

is inhibited by mutating the *pnp* start codon (Supplemental Figs. S4, S7). Likewise, inhibiting translation by SHX also reduces processing of SraG to SraGp (Supplemental Fig. S1). One attractive hypothesis would be a competition between *pnp* translation initiation and the interaction between *pnp* mRNA-SraG. We propose that initiation of *pnp* translation requires unfolding of the 5'UTR of the messenger, which enables an initial interaction to occur between the two RNA molecules. Once the ribosome leaves the SD sequence, this interaction can extend back to the 5'-end of SraG. Consequently, the 5' part of the SraG sRNA is paired very close to the *pnp* SD sequence (Fig. 1D), and it can further inhibit initiation of *pnp* translation, as shown by in vitro toeprinting (Fig. 6). Another consequence of the pairing between *pnp* mRNA and SraG could be that SraG adopts an alternative structure allowing its cleavage by an RNase, which remains to be identified, and could require a ribosome-associated factor. This cleavage would remove the 5'-end of SraG and generate an RNA unable to regulate the expression of *pnp*. In the absence of translation, the *pnp* mRNA is degraded

(Fig. 7B), SraG cannot interact with this messenger and remains in its initial structure, which does not allow the processing, giving rise to SraGp. In addition to an effect on *pnp* translation, the generation of SraGp could also depend upon PNPase catalytic activity (Fig. 2).

RNase III is the primary actor in *pnp* regulation since it initiates a cascade of events involving RNase E and PNPase (requiring its catalytic activity) that leads to the degradation of the *pnp* messenger. Cleavage by RNase III is also required for CsrA to repress *pnp* translation (Park et al. 2015). On the other hand, when RNase III is absent, PNPase can inhibit its own translation by competing with the binding of S1 on its own mRNA (Carzaniga et al. 2015). In the case of SraG, we observed regulation of *pnp* in the presence or absence of RNase III; this indicates that CsrA and SraG regulation might be independent. The role of SraG sRNA as another player in *pnp* regulation was not suspected before, probably because of the annotation error of its transcription start site. But a previously described mutation reducing PNPase autoregulation was located in the -10 sequence of the SraG promoter we described here, implying that SraG expression does impact *pnp* expression in vivo (Robert-Le Meur and Portier 1992).

Both SraG and *pnp* transcripts are more abundant in the absence of RNase III: *pnp* because of the absence of RNase III-dependent PNPase autoregulation and CsrA repression, and SraG because of its higher stability; SraG inhibition of *pnp* expression was strongest in the *rnc* strain (Fig. 3B). These results suggest that the SraG-mediated regulation of *pnp* may act as an additional factor in the control of PNPase expression to supplement its autoregulation and CsrA-dependent control of translation. The physiological role of SraG might be more important in conditions where RNase III activity is down-regulated, e.g., in response to stresses (Kim et al. 2008). This interplay in the control of SraG processing and PNPase expression thus contributes to PNPase homeostasis.

Potential SraG homologs located between the *pnp* and *rpsO* genes exist in various enterobacteria, such as *Salmonella typhimurium*, *Shigella flexneri*, and *Klebsiella pneumoniae* (Hershberg et al. 2003; Sridhar et al. 2009). All the *Yersinia* species exhibit the *rpsO-pnp* synteny (i.e., gene co-localization), but in *Yersinia pestis* an insertion element is annotated in the intergenic region of the *rpsO-pnp* operon. In *Listeria monocytogenes*, despite the same localization between the *pnpA* and *rpsO* genes, the RliD sRNA does not share high-sequence homology with SraG (Mandin et al. 2007). In *Enterococcus faecalis*, *ref41* is transcribed from the opposite strand to the highly conserved *pnpA* gene, and it includes a potential translatable 43 amino acids ORF (Fouquier d'Herouel et al. 2011). The synteny of *rpsO* and *pnp* genes exists in the majority of bacteria (Supplemental Fig. S9). However, there is no colocalization in the order of *Campylobacteriales* (Epsilon proteobacteria) and in many species of the Firmicutes. The regulation of *pnp* expression and a possible function of the sRNA has not been investigated in any of these bacteria.

The function of SraG was studied in *Yersinia pseudotuberculosis*. While no effect on *pnp* was reported, SraG was shown to negatively regulate the YPK_1206-1205 operon, which encodes genes that have no homologs outside the *Yersinia* genus (Lu et al. 2012). Other potential candidates were identified by proteomic analysis of the wt and Δ sraG mutant in this species but without further confirmation. Although we tried various strategies, we were unable to identify other putative SraG targets in *E. coli*. SraG may have additional targets in *E. coli*, which were not detected in our experimental conditions.

In spite of the redundancy in 3′–5′ exoribonucleases in *E. coli*, a *pnp* mutant exhibits specific phenotypes as compared to mutants deficient in RNase II or RNase R. In addition, PNPase is a component of the *E. coli* degradosome. A *pnp* mutant accumulates numerous RNA fragments produced by endoribonucleic cleavages due to a major defect in poly (A)-dependent degradation (Braun et al. 1996; Coburn and Mackie 1998). PNPase is involved in the turnover of sRNAs, the modulation of RNase II expression and in the processing of RliD-CRISPR in *Listeria* (Zilhao et al. 1996; Andrade and Arraiano 2008; De Lay and Gottesman 2011; Andrade et al. 2012; Sesto et al. 2014). PNPase enzymatic activity is dependent on magnesium-chelated citrate, ATP and c-di-GMP, thereby creating a network between metabolism and RNA turnover (Del Favero et al. 2008; Nurmohamed et al. 2011; Tuckerman et al. 2011). PNPase availability is a determinant for growth when bacteria are submitted to cold-shock, and for survival under oxidative stress, for UV radiation and for mitomycin C exposure (Zangrossi et al. 2000; Yamanaka and Inouye 2001; Haddad et al. 2009; Wu et al. 2009; Rath et al. 2012). PNPase is a global regulator of virulence and persistency in *Salmonella enterica*, and it has an impact on the physiology of *Campylobacter jejuni* (Clements et al. 2002; Haddad et al. 2012). It is clear that PNPase has specific roles in bacteria that cannot be fulfilled by the other 3′–5′ exoribonucleases. A tight control of the level of PNPase seems to be required for its pluripotent role in bacteria, and the results reported here indicate that SraG has a role in this fine-tuning in *E. coli*.

MATERIALS AND METHODS

Bacterial strains and plasmids

Bacterial strains, primers, and plasmids used in this work are listed in Supplemental Table S1. All constructions and mutations, described in the Supplemental Material, were confirmed by sequencing. Strains are derived from *E. coli* K12 MG1655 and N3433. Strains were grown in Luria-Bertani (LB) medium at 37°C or 30°C with appropriate antibiotics when needed.

β-Galactosidase activity

Twenty to 100 μM IPTG was added either at the beginning of the culture after diluting an overnight preculture to OD₆₀₀ = 0.025 or

during the exponential phase in cells containing pBRSraG or pBRSraG-S. Expression of the *lacZ* fusions was measured during the exponential phase. The cells were lysed in 800 μL Z buffer with 15 μL 0.1% SDS and 30 μL chloroform. β-Galactosidase activity was assayed as described by Miller (1972).

RNA extraction

Aliquots of 10 mL of cultures were mixed with 10 mL cold ethanol and stored at –20°C. After centrifugation, pellets were resuspended in 750 μL lysis buffer (0.5% SDS, 20 mM sodium acetate, 10 mM EDTA), 500 μL hot acid phenol (pH 4.5) was added, and samples were incubated at 65°C for 10 min. This step was repeated twice followed by a final extraction with chloroform. RNA were precipitated with ethanol, pellets were washed with 70% ethanol and resuspended in water. To determine RNA stability, rifampicin (500 μg/mL) was added to bacteria (OD₆₅₀ = 0.4) and samples were taken at different times.

Northern blot analysis

RNA samples were separated on 6% polyacrylamide-urea gel and blotted to Hybond N+ membranes (Hajnsdorf et al. 1994b) to detect SraG and *rpsO* transcripts or on 1% agarose-formaldehyde gel (Hajnsdorf et al. 1994a) to detect *pnp* mRNA. Riboprobes were generated by in vitro transcription of PCR fragments with T7 RNA polymerase in the presence of [α -³²P]UTP (Hajnsdorf and Régner 2000). Primers used to generate PCR fragments with a T7 promoter are listed in Supplemental Table S1. 5S rRNA was used as a loading control.

In vitro processing by RNase III

DNA templates carrying a T7 promoter sequence for in vitro transcription were generated by PCR using the primers mT7-pnp1 and RNX1 for *pnp*, T7mSraG2 and sraGter2 for SraG-S, and T7mSraG1 and sraGter2 for SraG (Supplemental Table S1). RNA substrates were obtained by transcription of the PCR fragments using T7 RNA polymerase and purified on denaturing 6% polyacrylamide-urea gels (Folichon et al. 2005). *pnp*, SraG, and SraG-S RNA sizes were 237, 216, and 177 nt, respectively, with additional GGG at the 5′-end. 5′-end labeling was performed with [γ -³²P]-ATP and T4 polynucleotide kinase (Folichon et al. 2005), 3′-end-labeling was performed with [³²P]-pCp and T4 RNA ligase in 50 mM HEPES (pH 7.5), 20 mM MgCl₂, 3 mM DTT, 0.1 mM ATP, 10% DMSO, 10 mg/mL BSA at 16°C for 16 h. The purified labeled RNAs in 1× TE were denatured and incubated 30 min at 37°C with the unlabeled complementary strand to allow them to anneal. Hybridization efficiency between *pnp* mRNA and SraG RNAs was controlled on nondenaturing polyacrylamide gels (Folichon et al. 2005). RNase III digestion was conducted in 50 mM Tris-HCl (pH 8.0), 100 mM NaCl, 10 mM MgCl₂, 0.1 mM DTT with increasing concentrations of RNase III (Epicentre) at 37°C for 30 min. After precipitation, addition of loading buffer and heat denaturation, samples were analyzed on 6% polyacrylamide-urea gels. Cleavage positions were identified by running radiolabeled DNA fragments, and RNase T1 and alkaline ladders of the same end-labeled RNA (Folichon et al. 2003).

Mapping of 5'- and 3'-extremities of RNA

To map RNase III cleavages on *pnf* mRNA, reverse transcription was performed with the radiolabeled RNX1 oligonucleotide and 5 µg total RNA by using Superscript II RT (Invitrogen). cDNAs were separated on a 6% polyacrylamide-urea gel.

To map 5'- and 3'-extremities of SraG, circular RT-PCR was performed with total RNA extracted from N3433 transformed by the pB15.6 plasmid to increase the gene dosage of the whole *nusA-infB* and *rpsO-pnf* operons (Plumbridge and Springer 1983; Braun et al. 1996). Plasmid DNA contamination was removed by DNase RQ1 digestion according to Promega's instructions. RNAs were re-extracted with phenol-chloroform and precipitated with ethanol. Five micrograms of RNA was treated with 20 units of 5'-polyphosphatase (Epicentre) to convert 5'-triphosphorylated RNA into 5'-monophosphorylated RNA. Five hundred nanograms of RNA treated or untreated by 5'-polyphosphatase were circularized with T4 RNA ligase (Biolabs) in denaturing buffer (50 mM HEPES, pH 7.5, 20 mM MgCl₂, 3 mM DTT, 0.1 mM ATP, 10% DMSO, 10 µg/µL BSA) and subjected to RT-PCR across the 5'/3' junction using the m423–442 primer to prime RT, then the oligonucleotide pair m1 and rpsO441 was used with the Triple Master Polymerase (Eppendorf) to generate PCR products, which were purified on agarose or acrylamide gels (Supplemental Fig. S2) and cloned into TOPO vector (Zero Blunt TOPOII Cloning, Invitrogen). Altogether, a total of 93 clones were sequenced and analyzed.

Toe-print analysis

The RNA fragments are the same as those used in the RNase III in vitro maturation assay. 1.2 pmol unlabeled *pnf* mRNA fragment (237 nt) and 4.8 pmol 5'-Cy5-end-labeled primer RNX1, an oligonucleotide complementary to nts 62–79 of *pnf* ORF were mixed with various amounts of SraG-S or SraG RNAs (0, 0.6, 1.2, 2.4, or 6 pmol). Two hundred and fifty micromolar dNTPs and 2.5 µM of initiator tRNA^{fMet} were added with 0.5 µM 30S subunits, and the mixtures were incubated at 37°C for 10 min. One unit AMV RT (Finnzymes) was then added and cDNA synthesis was performed at 37°C for 20 min (Coornaert et al. 2013). A sequencing ladder was produced by asymmetric PCR with the *pnf* PCR fragment (15 fmol/µL) amplified in the presence of 5'-Cy5-end-labeled primer RNX1 and one of the 4 ddNTP mixes (at a ratio ddNTP:dNTP of 25:1 except for ddGTP which was at a ratio of 2.5:1). cDNAs and sequence ladders were separated on a 6% polyacrylamide-urea gel and visualized using a Typhoon fluorescent scanner set up for Cy5 detection.

Computational SraG target search

We performed a target search for SraG using the RNAup program from the Vienna package (<http://www.tbi.univie.ac.at/RNA/RNAup.html>). The SraG and SraG-S sequences were compared to each annotated *E. coli* CDS plus 50 nt 5' to include the putative 5'UTR. Predicted sRNA/target pairs were ranked by free energy values, as estimated by RNAup.

Transcriptome analysis

Three independent cultures of FF4 cells transformed with the pBRplac (pBR), pBR-SraG (pSraG), and pBr-SraG short (pSraG-

S) plasmids were grown to exponential phase. SraG and SraG-S synthesis was induced with 100 µM IPTG addition at OD₆₀₀ = 0.4 for 7 min. RNA was extracted and incubated with DNase RQ1 (1 U/3 µg RNA). cDNAs were generated and labeled with either Cy3 or Cy5-Mono-Reactive Dye (Amersham) using the FairPlay III Microarrays Labeling Kit (Stratagene). Transcriptome experiments were performed with *E. coli* Gene Expression Microarrays 8 × 15 K (Agilent). Results were analyzed using two different statistical tests: Bonferroni and BH.

Western blotting

Frozen cells were resuspended in 0.1 M Tris-HCl (pH 8), 0.4 M NaCl, 0.1 mM EDTA, 1 mM 2-β-mercaptoethanol and lysed by sonication on ice. Protein concentrations were determined by the BCA protein assay (Pearce). Cellular proteins (10 µg) were separated on a 10% SDS-PAGE gel and transferred to Hybond C-super (Amersham) by electroblotting. Membranes were probed at the same time with 1/10,000 dilution of polyclonal PNPase antibodies and of polyclonal L20 antibodies followed by incubation with hRP anti-rabbit IgG in 5% milk. The membrane was developed using the kit Super Signal West Femto (Thermo Scientific).

SUPPLEMENTAL MATERIAL

Supplemental material is available for this article.

ACKNOWLEDGMENTS

We are indebted to D. Gautheret for comments and suggestions and to J. Plumbridge and K. Tanner for discussions and critical reading of the manuscript. We thank C. Chiaruttini for advice, L20 antibodies, and providing materials to perform the toe-print experiment, C. Guerrier-Takada and M.P. Deutscher for strains, and A.J. Carpousis for PNPase antibodies. The DNA array analysis was performed by the ArraySud Plateform. This work was supported by the Centre National de la Recherche Scientifique (UPR9073 then FRE3630 and now UMR8261), University Paris-Diderot and Agence Nationale de la Recherche (asSUPYCO, ANR-12-BSV6-0007-03), and by the "Initiative d'Excellence" program from the French State (Grant "DYNAMO," ANR-11-LABX-0011).

Received November 12, 2015; accepted June 24, 2016.

REFERENCES

- Andrade JM, Arraiano CM. 2008. PNPase is a key player in the regulation of small RNAs that control the expression of outer membrane proteins. *RNA* **14**: 543–551.
- Andrade JM, Pobre V, Silva JJ, Domingues S, Arraiano CM. 2009. The role of 3'-5' exoribonucleases in RNA degradation. *Prog Mol Biol Transl Sci* **85**: 187–229.
- Andrade JM, Pobre V, Matos AM, Arraiano CM. 2012. The crucial role of PNPase in the degradation of small RNAs that are not associated with Hfq. *RNA* **18**: 844–855.
- Argaman L, Hershberg R, Vogel J, Bejerano G, Wagner EGH, Margalit H, Altuvia S. 2001. Novel small RNA-encoding genes in the intergenic regions of *Escherichia coli*. *Curr Biol* **11**: 941–950.
- Bandrya KJ, Sinha D, Syrjanen J, Luisi BF, De Lay NR. 2016. The ribonuclease polynucleotide phosphorylase can interact with small

- regulatory RNAs in both protective and degradative modes. *RNA* **22**: 360–372.
- Beckett E, Tse L, Yung M, Cosico A, Miller JH. 2012. Polynucleotide phosphorylase plays an important role in the generation of spontaneous mutations in *Escherichia coli*. *J Bacteriol* **194**: 5613–5620.
- Beran RK, Simons RW. 2001. Cold-temperature induction of *Escherichia coli* polynucleotide phosphorylase occurs by reversal of its autoregulation. *Mol Microbiol* **39**: 112–125.
- Brantl S. 2007. Regulatory mechanisms employed by *cis*-encoded antisense RNAs. *Curr Opin Microbiol* **10**: 102–109.
- Braun F, Hajnsdorf E, Régner P. 1996. Polynucleotide phosphorylase is required for the rapid degradation of the RNase E-processed *rpsO* mRNA of *Escherichia coli* devoid of its 3' hairpin. *Mol Microbiol* **19**: 997–1005.
- Carpousis AJ, van Houwe G, Ehretsmann C, Krisch HM. 1994. Co-purification of *E. coli* RNase E and PNPase: evidence for a specific association between two enzymes important in RNA processing and degradation. *Cell* **76**: 889–900.
- Carpousis AJ, Luisi BF, McDowall KJ. 2009. Endonucleolytic initiation of mRNA decay in *Escherichia coli*. *Prog Mol Biol Transl Sci* **85**: 91–135.
- Carzaniga T, Briani F, Zangrossi S, Merlino G, Marchi P, Dehò G. 2009. Autogenous regulation of *Escherichia coli* polynucleotide phosphorylase expression revisited. *J Bacteriol* **191**: 1738–1748.
- Carzaniga T, Dehò G, Briani F. 2015. RNase III-independent autogenous regulation of *Escherichia coli* polynucleotide phosphorylase via translational repression. *J Bacteriol* **197**: 1931–1938.
- Chen X, Taylor DW, Fowler CC, Galan JE, Wang HW, Wolin SL. 2013. An RNA degradation machine sculpted by Ro autoantigen and non-coding RNA. *Cell* **153**: 166–177.
- Clements MO, Eriksson S, Thompson A, Lucchini S, Hinton JC, Normark S, Rhen M. 2002. Polynucleotide phosphorylase is a global regulator of virulence and persistency in *Salmonella enterica*. *Proc Natl Acad Sci* **99**: 8784–8789.
- Coburn GA, Mackie GA. 1998. Reconstitution of the degradation of the mRNA for ribosomal protein S20 with purified enzymes. *J Mol Biol* **279**: 1061–1074.
- Coornaert A, Chiaruttini C, Springer M, Guillier M. 2013. Post-transcriptional control of the *Escherichia coli* PhoQ-PhoP two-component system by multiple sRNAs involves a novel pairing region of GcvB. *PLoS Genet* **9**: e1003156.
- Court DL, Gan J, Liang YH, Shaw GX, Tropea JE, Costantino N, Waugh DS, Ji X. 2013. RNase III: genetics and function; structure and mechanism. *Annu Rev Genet* **47**: 405–431.
- Darfeuille F, Unoson C, Vogel J, Wagner EG. 2007. An antisense RNA inhibits translation by competing with standby ribosomes. *Mol Cell* **26**: 381–392.
- Davies BW, Kohrer C, Jacob AI, Simmons LA, Zhu J, Aleman LM, Rajbhandary UL, Walker GC. 2010. Role of *Escherichia coli* YbeY, a highly conserved protein, in rRNA processing. *Mol Microbiol* **78**: 506–518.
- De Lay N, Gottesman S. 2011. Role of polynucleotide phosphorylase in sRNA function in *Escherichia coli*. *RNA* **17**: 1172–1189.
- Del Favero M, Mazzantini E, Briani F, Zangrossi S, Tortora P, Dehò G. 2008. Regulation of *Escherichia coli* polynucleotide phosphorylase by ATP. *J Biol Chem* **283**: 27355–27359.
- Folichon M, Arluison V, Pellegrini O, Huntzinger E, Régner P, Hajnsdorf E. 2003. The poly(A) binding protein Hfq protects RNA from RNase E and exoribonucleolytic degradation. *Nucleic Acids Res* **31**: 7302–7310.
- Folichon M, Allemand F, Régner P, Hajnsdorf E. 2005. Stimulation of poly(A) synthesis by *E. coli* poly(A) polymerase I is correlated with Hfq binding to poly(A) tails. *FEBS J* **272**: 454–463.
- Fouquier d'Herouel A, Wessner F, Halpern D, Ly-Vu J, Kennedy SP, Serró P, Aurell E, Repoila F. 2011. A simple and efficient method to search for selected primary transcripts: non-coding and antisense RNAs in the human pathogen *Enterococcus faecalis*. *Nucleic Acids Res* **39**: e46.
- Gerdes K, Wagner EG. 2007. RNA antitoxins. *Curr Opin Microbiol* **10**: 117–124.
- Gerdes K, Christensen SK, Løbner-Olesen A. 2005. Prokaryotic toxin-antitoxin stress response loci. *Nat Rev Microbiol* **3**: 371–382.
- Gopel Y, Papenfort K, Reichenbach B, Vogel J, Görke B. 2013. Targeted decay of a regulatory small RNA by an adaptor protein for RNase E and counteraction by an anti-adaptor RNA. *Genes Dev* **27**: 552–564.
- Goverde RL, Huis in't Veld JH, Kusters JG, Mooi FR. 1998. The psychrotrophic bacterium *Yersinia enterocolitica* requires expression of *pnp*, the gene for polynucleotide phosphorylase, for growth at low temperature (5°C). *Mol Microbiol* **28**: 555–569.
- Grunberg-Manago M, Oritz PJ, Ochoa S. 1955. Enzymatic synthesis of nucleic acid like polynucleotides. *Science* **122**: 907–910.
- Guillier M, Gottesman S. 2006. Remodelling of the *Escherichia coli* outer membrane by two small regulatory RNAs. *Mol Microbiol* **59**: 231–247.
- Haddad N, Burns CM, Bolla JM, Prévost H, Federighi M, Drider D, Cappelletti JM. 2009. Long-term survival of *Campylobacter jejuni* at low temperatures is dependent on polynucleotide phosphorylase activity. *Appl Environ Microbiol* **75**: 7310–7318.
- Haddad N, Tresse O, Rivoal K, Chevreton D, Nonglaton Q, Burns CM, Prévost H, Cappelletti JM. 2012. Polynucleotide phosphorylase has an impact on cell biology of *Campylobacter jejuni*. *Front Cell Infect Microbiol* **2**: 30.
- Hajnsdorf E, Régner P. 2000. Host factor Hfq of *Escherichia coli* stimulates elongation of poly(A) tails by poly(A) polymerase I. *Proc Natl Acad Sci* **97**: 1501–1505.
- Hajnsdorf E, Carpousis AJ, Régner P. 1994a. Nucleolytic inactivation and degradation of the RNase III processed *pnp* message encoding polynucleotide phosphorylase of *Escherichia coli*. *J Mol Biol* **239**: 439–454.
- Hajnsdorf E, Steier O, Coscoy L, Teyssset L, Régner P. 1994b. Roles of RNase E, RNase II and PNPase in the degradation of the *rpsO* transcripts of *Escherichia coli*: stabilizing function of RNase II and evidence for efficient degradation in an *ams-rmb-pnp* mutant. *EMBO J* **13**: 3368–3377.
- Hershberg R, Altuvia S, Margalit H. 2003. A survey of small RNA-encoding genes in *Escherichia coli*. *Nucleic Acids Res* **31**: 1813–1820.
- Ito A, May T, Taniuchi A, Kawata K, Okabe S. 2009. Localized expression profiles of rpoS in *Escherichia coli* biofilms. *Biotechnol Bioeng* **103**: 975–983.
- Jarrige AC, Mathy N, Portier C. 2001. PNPase autocontrols its expression by degrading a double-stranded structure in the *pnp* mRNA leader. *EMBO J* **20**: 6845–6855.
- Kawano M, Aravind L, Storz G. 2007. An antisense RNA controls synthesis of an SOS-induced toxin evolved from an antitoxin. *Mol Microbiol* **64**: 738–754.
- Kim KS, Manasherob R, Cohen SN. 2008. YmdB: a stress-responsive ribonuclease-binding regulator of *E. coli* RNase III activity. *Genes Dev* **22**: 3497–3508.
- Le Derout J, Boni IV, Regnier P, Hajnsdorf E. 2010. Hfq affects mRNA levels independently of degradation. *BMC Mol Biol* **11**: 17.
- Lu P, Zhang Y, Li L, Hu Y, Huang L, Li Y, Rayner S, Chen S. 2012. Small non-coding RNA SraG regulates the operon YPK_1206-1205 in *Yersinia pseudotuberculosis*. *FEMS Microbiol Lett* **331**: 37–43.
- Luttinger A, Hahn J, Dubnau D. 1996. Polynucleotide phosphorylase is necessary for competence development in *Bacillus subtilis*. *Mol Microbiol* **19**: 343–356.
- Maes A, Gracia C, Hajnsdorf E, Régner P. 2012. Search for poly(A) polymerase targets in *E. coli* reveals its implication in surveillance of Glu tRNA processing and degradation of stable RNAs. *Mol Microbiol* **83**: 436–451.
- Mandin P, Repoila F, Vergassola M, Geissmann T, Cossart P. 2007. Identification of new noncoding RNAs in *Listeria monocytogenes* and prediction of mRNA targets. *Nucleic Acids Res* **35**: 962–974.
- Massé E, Escorcia FE, Gottesman S. 2003. Coupled degradation of a small regulatory RNA and its mRNA targets in *Escherichia coli*. *Genes Dev* **17**: 2374–2383.

- Mathy N, Jarrige AC, Robert-Le Meur M, Portier C. 2001. Increased expression of *Escherichia coli* polynucleotide phosphorylase at low temperatures is linked to a decrease in the efficiency of autocontrol. *J Bacteriol* **183**: 3848–3854.
- Miller J. 1972. *Experiments in molecular genetics*. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
- Numata S, Nagata M, Mao H, Sekimizu K, Kaito C. 2014. CvfA protein and polynucleotide phosphorylase act in an opposing manner to regulate *Staphylococcus aureus* virulence. *J Biol Chem* **289**: 8420–8431.
- Nurmohamed S, Vincent HA, Titman CM, Chandran V, Pears MR, Du D, Griffin JL, Callaghan AJ, Luisi BF. 2011. Polynucleotide phosphorylase activity may be modulated by metabolites in *Escherichia coli*. *J Biol Chem* **286**: 14315–14323.
- Opdyke JA, Kang JG, Storz G. 2004. GadY, a small-RNA regulator of acid response genes in *Escherichia coli*. *J Bacteriol* **186**: 6698–6705.
- Opdyke JA, Fofo EM, Hemm MR, Storz G. 2011. RNase III participates in GadY-dependent cleavage of the *gadX-gadW* mRNA. *J Mol Biol* **406**: 29–43.
- Pandey SP, Minesinger BK, Kumar J, Walker GC. 2011. A highly conserved protein of unknown function in *Sinorhizobium meliloti* affects sRNA regulation similar to Hfq. *Nucleic Acids Res* **39**: 4691–4708.
- Park H, Yakhnin H, Connolly M, Romeo T, Babitzke P. 2015. CsrA participates in a PNPase autoregulatory mechanism by selectively repressing translation of *pnp* transcripts that have been previously processed by RNase III and PNPase. *J Bacteriol* **197**: 3751–3759.
- Plumbridge JA, Springer M. 1983. Organization of the *Escherichia coli* chromosome around the genes for translation initiation factor IF2 (*inf2*) and a transcription terminator factor (*nusA*). *J Mol Biol* **167**: 227–243.
- Portier C, Régnier P. 1984. Expression of the *rpsO* and *pnp* genes: structural analysis of a DNA fragment carrying their control regions. *Nucleic Acids Res* **12**: 6091–6102.
- Portier C, Dondon L, Grunberg-Manago M, Régnier P. 1987. The first step in the functional inactivation of the *Escherichia coli* polynucleotide phosphorylase messenger is a ribonuclease III processing at the 5' end. *EMBO J* **6**: 2165–2170.
- Rath D, Mangoli SH, Pagedar AR, Jawali N. 2012. Involvement of *pnp* in survival of UV radiation in *Escherichia coli* K-12. *Microbiology* **158** (Pt 5): 1196–1205.
- Régnier P, Grunberg-Manago M. 1990. RNase III cleavages in non-coding leaders of *Escherichia coli* transcripts control mRNA stability and genetic expression. *Biochimie* **72**: 825–834.
- Régnier P, Hajnsdorf E. 1991. Decay of mRNA encoding ribosomal protein S15 of *Escherichia coli* is initiated by an RNaseE-dependent endonucleolytic cleavage that removes the 3' stabilizing stem and loop structure. *J Mol Biol* **217**: 283–292.
- Régnier P, Hajnsdorf E. 2009. Poly(A)-assisted RNA decay and modulators of RNA stability. *Prog Mol Biol Transl Sci* **85**: 137–185.
- Reichenbach B, Maes A, Kalamorz F, Hajnsdorf E, Görke B. 2008. The small RNA GlmY acts upstream of the sRNA GlmZ in the activation of *glmS* expression and is subject to regulation by polyadenylation in *Escherichia coli*. *Nucleic Acids Res* **36**: 2570–2580.
- Reuven NB, Zhou Z, Deutscher MP. 1997. Functional overlap of tRNA nucleotidyltransferase, poly(A)polymearse I and polynucleotide phosphorylase. *J Biol Chem* **272**: 33255–33259.
- Robert-Le Meur M, Portier C. 1992. *E. coli* polynucleotide phosphorylase expression is autoregulated through an RNase III-dependent mechanism. *EMBO J* **11**: 2633–2641.
- Robert-Le Meur M, Portier C. 1994. Polynucleotide phosphorylase of *Escherichia coli* induces the degradation of its RNase III processed messenger by preventing its translation. *Nucleic Acids Res* **22**: 397–403.
- Rosenzweig JA, Chromy B, Echeverry A, Yang J, Adkins B, Plano GV, McCutchen-Maloney S, Schesser K. 2007. Polynucleotide phosphorylase independently controls virulence factor expression levels and export in *Yersinia* spp. *FEMS Microbiol Lett* **270**: 255–264.
- Sesto N, Touchon M, Andrade JM, Kondo J, Rocha EP, Arraiano CM, Archambaud C, Westhof E, Romby P, Cossart P. 2014. A PNPase dependent CRISPR System in *Listeria*. *PLoS Genet* **10**: e1004065.
- Sridhar J, Kumar SS, Rafi ZA. 2009. Small RNA identification in Enterobacteriaceae using synteny and genomic backbone retention II. *OMICS* **13**: 261–284.
- Thomason MK, Storz G. 2010. Bacterial antisense RNAs: how many are there, and what are they doing? *Annu Rev Genet* **44**: 167–188.
- Tuckerman JR, Gonzalez G, Gilles-Gonzalez MA. 2011. Cyclic di-GMP activation of polynucleotide phosphorylase signal-dependent RNA processing. *J Mol Biol* **407**: 633–639.
- Vogel J, Luisi BF. 2011. Hfq and its constellation of RNA. *Nat Rev Microbiol* **9**: 578–589.
- Vogel J, Bartels V, Tang TH, Churakov G, Slagter-Jager JG, Huttenhofer A, Wagner EG. 2003. RNomics in *Escherichia coli* detects new sRNA species and indicates parallel transcriptional output in bacteria. *Nucleic Acids Res* **31**: 6435–6443.
- Wagner EGH, Blomberg P, Nordström K. 1992. Replication control in plasmid R1: duplex formation between the antisense RNA, CopA and its target CopT is not required for inhibition of RepA synthesis. *EMBO J* **11**: 1195–1203.
- Wu J, Jiang Z, Liu M, Gong X, Wu S, Burns CM, Li Z. 2009. Polynucleotide phosphorylase protects *Escherichia coli* against oxidative stress. *Biochemistry* **48**: 2012–2020.
- Yamanaka K, Inouye M. 2001. Selective mRNA degradation by polynucleotide phosphorylase in cold shock adaptation in *Escherichia coli*. *J Bacteriol* **183**: 2808–2816.
- Zangrossi S, Briani F, Ghisotti D, Regonesi ME, Tortora P, Dehò G. 2000. Transcriptional and post-transcriptional control of polynucleotide phosphorylase during cold acclimation in *Escherichia coli*. *Mol Microbiol* **36**: 1470–1480.
- Zhang A, Wassarman KM, Rosenow C, Tjaden BC, Storz G, Gottesman S. 2003. Global analysis of small RNA and mRNA targets of Hfq. *Mol Microbiol* **50**: 1111–1124.
- Zilhao R, Cairrao F, Régnier P, Arraiano CM. 1996. PNPase modulates RNase II expression in *Escherichia coli*: implications for mRNA decay and cell metabolism. *Mol Microbiol* **20**: 1033–1042.
- Zuo Y, Deutscher MP. 2001. Exoribonuclease superfamilies: structural analysis and phylogenetic distribution. *Nucleic Acids Res* **29**: 1017–1026.

RNA

A PUBLICATION OF THE RNA SOCIETY

The small RNA SraG participates in PNPase homeostasis

Fanette Fontaine, Elise Gasiorowski, Celine Gracia, et al.

RNA 2016 22: 1560-1573 originally published online August 5, 2016

Access the most recent version at doi:[10.1261/rna.055236.115](https://doi.org/10.1261/rna.055236.115)

Supplemental Material

<http://rnajournal.cshlp.org/content/suppl/2016/08/05/rna.055236.115.DC1>

References

This article cites 79 articles, 23 of which can be accessed free at:
<http://rnajournal.cshlp.org/content/22/10/1560.full.html#ref-list-1>

Creative Commons License

This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see <http://rnajournal.cshlp.org/site/misc/terms.xhtml>). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

To subscribe to *RNA* go to:

<http://rnajournal.cshlp.org/subscriptions>